SecBot SecBot
8-K ·Filed May 8, 2026

AVAI

AVAI BIO, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001740797-26-000011
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

The termination removes a potential growth catalyst tied to AI healthcare technology. Monitor AVAI for any new strategic direction or partnership announcements, as the company is now operating without the joint venture's pipeline.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AVAI ▼ -55.36% at T+60d
NEUTRAL call -55.36% · α vs SPY -59.75% · entry $0.2800 → $0.1250
Entry = T+0 close
May 8, 2026
via day close
T+1d
+10.71%
call +10.71% · α +10.85%
$0.3100
settled 6mo ago
T+5d
+8.57%
call +8.57% · α +8.66%
$0.3040
settled 6mo ago
T+20d
-41.07%
call -41.07% · α -40.77%
$0.1650
settled 5mo ago
T+60d
-55.36%
call -55.36% · α -59.75%
$0.1250
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

AVAI Bio and Ainnova Tech mutually terminated their Joint Venture and License Agreement dated November 8, 2024, and agreed to dissolve their joint venture entity, Ai-Nova Acquisition Corp. No termination penalties or further financial obligations were incurred by either party. This filing represents a strategic retreat from the AI healthcare joint venture, with no financial details disclosed.

Key Facts

  • Mutual termination of Joint Venture and License Agreement dated November 8, 2024, effective May 7, 2026.
  • Joint venture entity Ai-Nova Acquisition Corp. (AAC) to be formally dissolved.
  • No termination penalties or further financial obligations for either party.
  • Each party retains its own intellectual property; all licenses under the agreement are revoked.
  • AVAI and Ainnova will pursue their respective business strategies independently.

Financial Impact

No financial consideration, penalties, or material obligations disclosed in the filing.

Risk Factors

  • Loss of potential revenue and technology synergies from the terminated joint venture.
  • Uncertainty about AVAI's future business strategy and ability to generate value independently.

Market Snapshot

Exchange
OTC
Sector
Services-Computer Processing & Data Preparation

Investment Themes

Software & IT

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001740797-26-000011
Exhibit: exhibit10_1.htm0001740797-26-000011
Document: 0001740797-26-000011-index-headers.html0001740797-26-000011
Document: 0001740797-26-000011-index.html0001740797-26-000011
Document: 0001740797-26-000011.txt0001740797-26-000011

US Market Status

Market Open — Closes in 4h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026